Skip to content

EFFICACY OF MEDITATION IN GENERALIZED ANXIETY DISORDER

V. Vahia, H. Shetty, Shakera Motiwala, Gira Thakkar, L. Fernandes, J. Sharma

Indian Journal of Psychiatry April 1, 1993

Study at a glance

AI-extracted from the abstract
Characteristics Comparative clinical trial Peer reviewed
Population People with Generalized Anxiety Disorder
Interventions Meditation imipramine chlordiazepoxide
Duration 5 weeks
Measures TMAS
Topics Anxiety Meditation
Key findings After five weeks, meditation was reported to be as effective as imipramine and chlordiazepoxide in controlling anxiety symptoms, and superior in altering trait anxiety measured by TMAS scores. The authors argue meditation is easy to learn, cost effective, and free of habit formation, withdrawal effects, and overdosage risks.

Abstract

A study was conducted to compare the efficacy of meditation with that of imipramine and chlordiazepoxide in the treatment of Generalized Anxiety Disorder. At the end of five weeks, meditation was found to be as effective as pharmacotherapy in controlling symptoms of anxiety. It was superior in altering trait anxiety (TMAS Scores). Meditation is an easy to learn and cost effective therapy. It has a distinct edge over pharmacotherapy in that it is does not have the associated problems of habit formation,-withdrawal effects, overdosage or other undesirable effects.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Explore topics